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Background: Cigarette smoking adversely affects lipid proﬁles, and smoking cessation should improve
lipid proﬁles in the long term.However, it remains unclearwhether intensive,medication-based smoking
cessation therapy can affect lipid proﬁles in the short term. Thus, we evaluated the short-term effects of
smoking cessation therapy with varenicline on lipid proﬁles.
Methods:Participants included86 consecutive subjectswho received12weeks of smoking cessation ther-
apy. All subjects were treated with varenicline, and no changes were made to their current lipotropic and
antidiabetic medications during treatment. At ﬁrst and last visits, lipid proﬁles and fasting blood glucose
and hemoglobin A1c levels were evaluated and physical examination was performed. The success group,
comprising subjects who attained exhaled carbon monoxide-conﬁrmed 4-week continuous abstinence,
included 69 subjects, whereas the failure group, comprising thosewhodid not achieve complete smoking
cessation, included 17 subjects. The number of cigarettes consumed per day was reduced in all subjects
in the failure group.
Results: Serum apolipoprotein A-I (apoA-I) and high-density lipoprotein cholesterol (HDL-C) levels
signiﬁcantly increased from baseline to 12 weeks in the success group (apoA-I: 151.7±28.0 vs.
158.6±27.3mg/dL, respectively,p<0.01;HDL-C: 54.6±15.7vs. 57.9±14.3mg/dL, respectively,p<0.01);
however, there were no statistically signiﬁcant differences observed in the failure group (apoA-
I, 145.9±33.4 vs. 146.8±34.2mg/dL, respectively, p=0.87; HDL-C, 52.6±15.7 vs. 53.3±16.3mg/dL,
respectively, p=0.80). The effect sizes (Cohen’s d) of apoA-I and HDL-C in the success group were 0.42
and 0.46, respectively. The post hoc statistical power values of apoA-I and HDL-C in the success group
were 0.94 and 0.96, respectively.
Conclusion: These ﬁndings suggest that successful smoking cessation therapy with varenicline improves
serum apoA-I and HDL-C levels in the short term.
4 Jap© 201
ntroduction
High-density lipoprotein (HDL) has diverse antiatherogenic
unctions that include not only cholesterol efﬂux and reverse
holesterol transport, but also antioxidative, anti-inﬂammatory,
nd antithrombotic activities [1–4]. There is extensive evidence
hat high serum HDL cholesterol (HDL-C) levels, particularly high
evels of apolipoprotein A-I (apoA-I), which is a major protein in
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HDL, are associated with a reduced risk of coronary heart disease
(CHD) [5,6].
Cigarette smoking is the most important preventable cause of
cardiovascular disease [7]; it causes inﬂammation and oxidative
stress and leads to vasomotor dysfunction and altered blood coag-
ulation [8]. Moreover, a meta-analysis by Craig et al. previously
showed that smokers had signiﬁcantly lower serum HDL-C and
apoA-I levels than non-smokers and that this association was dose
dependent [9]. It has also been reported that smoking cessation
with the help of a counseling program increased the levels of
apoA-I and HDL-C [10,11]. However, it remains unclear whether
intensive smoking cessation therapy can affect lipid proﬁles in the
short term. It also remains unknown whether for subjects who
do not achieve complete cessation, simply reducing the number
of cigarettes smoked can improve lipid proﬁles in the short term.
served.
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e believe it is important to examine whether in comparison with
imply reducing the number of cigarettes smoked per day, com-
lete smoking cessation can contribute to a greater short-term
mprovement in lipid proﬁles. Therefore, we evaluated the short-
erm effects of smoking cessation therapy with varenicline on lipid
roﬁles, comparing the results between subjects who succeeded
n complete smoking cessation and those who simply reduced the
umber of cigarettes smoked per day.
ethods
ubjects
One-hundredandeighty-seven subjects presented toTokyoKita
ocial Insurance Hospital and expressed a desire to quit smoking
rom August 2010 to April 2013. Of these, 133 actually com-
leted 12 weeks of smoking cessation therapy with varenicline.
ll subjects fulﬁlled the following criteria: (1) 20 years of age or
lder, (2) Brinkman index (number of cigarettes per day times
moking years) score of ≥200, (3) Tobacco Dependence Screener
core of ≥5 [12], and (4) stated motivation to immediately quit
moking. These criteria were established by the Japanese medi-
al insurance system fornicotine-dependentoutpatients. Exclusion
riteria included undergoing an operation, receiving chemother-
py, receiving hemodialysis, contracting an infectious disease, and
Fig. 1. Flow chart for the selectiology 64 (2014) 318–323 319
experiencing an injury at any time from 3 months before the ﬁrst
visit to completion of smoking cessation therapy. Subjects whose
lipotropic or antidiabetic medications were changed within the
same3-monthperiodbeforeorduring the studywerealsoexcluded
to preclude the inﬂuence of these changes on lipid proﬁles and
glycometabolism during the therapy. Finally, 86 consecutive sub-
jects who received 12 weeks of smoking cessation therapy with
varenicline and fulﬁlled the aforementioned criteria were included
in this study. Patient selection is summarized in Fig. 1. Written
informed consent was obtained from all subjects, and this study
was approved by the ethics committee at Tokyo Kita Social Insur-
ance Hospital.
Smoking cessation therapy with varenicline
All subjects were prescribed varenicline titrated up to 1.0mg
twice daily (0.5mg once daily for 3 days, then 0.5mg twice daily for
4 days, then 1.0mg twice daily for 11 weeks). The target smoking
cessation date was planned to be 7 days after varenicline initiation.
After the ﬁrst visit on day 1, follow-up visits were scheduled on
days 15, 29, 57, and 85. Self-reported smoking status and exhaled
carbon monoxide concentrations were assessed at each visit. The
criterion for inclusion in the success group was exhaled carbon
monoxide-conﬁrmed 4-week continuous abstinence during weeks
9–12. This was deﬁned as the proportion of subjects who reported
ion of study participants.
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Table 1
Baseline characteristics of study subjects.
Success
group (n=69)
Failure group
(n=17)
p value
Age 60.2±11.3 60.4±11.7 0.97
Female (%) 28 (40.6%) 5 (29.4%) 0.40
Body weight (kg) 62.1±11.4 61.6±12.6 0.88
Body mass index 23.5±3.6 22.9±3.9 0.68
Number of years smoked 38.1±12.2 38.8±11.3 0.83
Number of cigarettes per day 22.6±10.5 21.9±11.5 0.80
Brinkman index 865±512 834±485 0.82
Triglycerides (mg/dL) 134.6±107.9 117.5±60.6 0.53
Total cholesterol (mg/dL) 192.8±33.7 196.9±49.5 0.69
HDL-C (mg/dL) 54.6±15.7 52.6±15.7 0.64
LDL-C (mg/dL) 112.2±31.9 120.7±43.1 0.36
ApoA-I (mg/dL) 151.7±28.0 145.9±33.4 0.46
Fasting glucose (mg/dL) 110.5±35.2 104.8±19.9 0.52
Hemoglobin A1c (%) 6.3±1.1 6.1±0.6 0.49
loge-CRP (mg/dL) −2.91±1.22 −3.01±1.73 0.80
Hypertension (%) 31 (44.9%) 10 (58.8%) 0.30
Dyslipidemia (%) 38 (55.1%) 11 (64.7%) 0.47
Diabetes mellitus (%) 18 (26.1%) 5 (29.4%) 0.77
Medication
Statins (%) 12 (17.4%) 3 (17.6%) 1.00
Fibrates (%) 3 (4.3%) 0 (0.0%) 1.00
Antidiabetic agents (%) 12 (17.4%) 1 (5.9%) 0.45
Insulin (%) 3 (4.3%) 0 (0.0%) 1.00
ACE-I/ARB (%) 19 (27.5%) 7 (41.2%) 0.27
-Blocker (%) 6 (8.7%) 1 (5.9%) 1.00
Data are expressed as the mean value± S.D. or frequency (%) of patients. HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
ApoA-I, apolipoprotein A-I; CRP, C-reactive protein; ACE-I, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker.
Table 2
Change of self-reported number of cigarettes smoked per day in the failure group.
Sex Age Self-reported number of
cigarettes at baseline
Self-reported number of
cigarettes at last visit
Female 69 20 per day 10 per day
Male 60 40 per day 10 per day
Male 60 40 per day 5 per day
Male 63 15 per day A few per day
Male 61 15 per day A few per day
Male 72 15 per day A few per 4 weeks
Male 69 12 per day A few per 4 weeks
Female 73 20 per day A few per 4 weeks
Male 38 20 per day A few per 4 weeks
Female 41 30 per day A few per 4 weeks
Male 52 20 per day A few per 4 weeks
Male 61 50 per day A few per 4 weeks
Female 48 10 per day A few per 4 weeks
Male 53 20 per day A few per 4 weeks
Male 58 10 per day A few per 4 weeks
Female 75 15 per day 0 (exhaled CO 13ppm)20 M. Iwaoka et al. / Journal o
o smoking during this period; this was conﬁrmed by an exhaled
arbon monoxide measurement of ≤10 parts per million at the
nal visit [13].
lood sampling
Venous blood samples were obtained after overnight fasting
rom all subjects at the ﬁrst and last visits. All serum samples were
nalyzed for total cholesterol (TC), triglycerides (TG), HDL-C, C-
eactive protein (CRP), fasting glucose, hemoglobin A1c (HbA1c),
nd apoA-I. TC, TG,HDL-C, andCRP levelsweremeasuredwithin 1h
fter sampling. Further, serum samples collected in a tube contain-
ng sodium ﬂuoride were analyzed for fasting glucose and HbA1c
evels within 1h after sampling. HbA1c values were determined
sing National Glycohemoglobin Standardization Program. Lev-
ls of apoA-I were measured using samples refrigerated at 4 ◦C
nd analyzed within 2 days after sampling with a turbidimetric
mmunoassay kit at a commercially available laboratory (Mit-
ubishi Chemical Medience Co., Tokyo, Japan). Serum low-density
ipoprotein cholesterol (LDL-C) levels were calculated using the
riedewald formula: LDL-C=TC−HDL-C−TG/5 [14].
tatistical analysis
Mean values in the success and failure groups were compared
sing unpaired t-test, whereas those for the ﬁrst (baseline) and last
isits in both groups were compared using paired t-test. The fre-
uencies between the groups were compared using chi-square test
r Fisher’s exact test. CRP levels were analyzed using a log transfor-
ation, because the distributions of CRP levels were not Gaussian.
he correlationbetweenapoA-I and loge-CRP levels fromtheﬁrst to
he last visit was analyzed using correlation analysis. All tests were
wo-tailed, and p<0.05was used to indicate statistical signiﬁcance.
nalyses were performed using PASW Statistics software version
8.0 (SPSS Inc., Chicago, IL, USA). The G* power 3 program (Erd-
elder, Faul, & Buchner,Mannheim, Germany)was used to calculate
ffect sizes and perform post hoc power analyses [15].
esults
Of the 86 study subjects, 69 met the criteria for the success
roup. Their baseline clinical characteristics are shown in Table 1.
here were no signiﬁcant differences between the success and fail-
re groups with regard to clinical characteristics including age,
ender, bodyweight, bodymass index, smoking status, lipidproﬁle,
asting glucose, HbA1c, loge-CRP, and use of statins and antidiabetic
gents. As shown in Table 2, all the subjects in the failure group
eported a reduction in the number of cigarettes smoked per day
rom the ﬁrst to the last visit. Two subjects in the failure group
eported no smoking during the ﬁnal 4 weeks of therapy; however,
heir exhaled carbon monoxide levels were >10 parts per million
t the last visit.
As shown in Table 3, despite a signiﬁcant mean gain in body
eight over 12 weeks (62.1±11.4 vs. 63.4±11.2 kg, respectively,
< 0.01), serum apoA-I and HDL-C levels signiﬁcantly increased
fter smoking cessation therapy in the success group (apoA-I:
51.7±28.0 vs. 158.6±27.3mg/dL, respectively, p<0.01; HDL-C:
4.6±15.7 vs. 57.9±14.3mg/dL, respectively, p<0.01). loge-CRP
evels also signiﬁcantly decreased after smoking cessation therapy
n the success group (−2.91±1.22 vs. −3.17±0.97mg/dL, respec-
ively, p=0.04). There were no signiﬁcant differences in the levels
f LDL-C, fasting glucose, andHbA1c in the success group. The effect
izes (Cohen’s d) of apoA-I, HDL-C, and body weight were greater
han those of LDL-C, fasting glucose, HbA1c, and loge-CRP, and the
ost hoc statistical power of apoA-I, HDL-C, and body weight were
0.9 (Table 3).Male 61 20 per day 0 (exhaled CO 12ppm)
CO, carbon monoxide; ppm, parts per milion.
In the failure group, therewereno signiﬁcantdifferences inbody
weight or in the levels of HDL-C, LDL-C, apoA-I, fasting glucose, and
HbA1c between baseline and last visit (Table 4). Moreover, loge-
CRP levels actually signiﬁcantly increased after smoking cessation
therapy in the failure group (−3.01±1.73 vs. −2.06±1.52mg/dL,
respectively, p=0.04). The effect sizes of apoA-I and HDL-C in the
failure group were <0.1 (Table 4).
Serum levels of apoA-I of all study subjects had a signiﬁcant
inverse correlation with loge-CRP levels on both the ﬁrst and the
last visits (Fig. 2).Discussion
Signiﬁcant body weight gain is usually associated with
a decrease in serum HDL-C and apoA-I levels, which are
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Table 3
Change of variables and post hoc power analysis in the success group.
Baseline Last visit p value Correlation coefﬁcient
between baseline and last visit
Cohen’s d Post hoc power
Body weight (kg) 62.1 ± 11.4 63.9 ± 11.2 <0.01 0.99 0.81 0.9999998
Triglycerides (mg/dL) 134.6 ± 107.9 128.3 ± 97.1 0.40 0.82 0.10 0.13
HDL-C (mg/dL) 54.6 ± 15.7 57.9 ± 14.3 <0.01 0.89 0.46 0.96
LDL-C (mg/dL) 112.2 ± 31.9 117.9 ± 32.0 0.05 0.73 0.24 0.51
ApoA-I (mg/dL) 151.7 ± 28.0 158.6 ± 27.3 <0.01 0.83 0.42 0.94
Fasting glucose (mg/dL) 110.5 ± 35.2 114.4 ± 41.3 0.13 0.86 0.19 0.34
Hemoglobin A1c (%) 6.3 ± 1.1 6.3 ± 1.2 0.44 0.93 0.00 0.05
loge-CRP (mg/dL) −2.91 ± 1.22 −3.17 ± 0.97 0.04 0.60 0.26 0.56
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA-I, apolipoprotein A-I; CRP, C-reactive protein.
Table 4
Change of variables and post hoc power analysis in the failure group.
Baseline Last visit p value Correlation coefﬁcient
between baseline and last visit
Cohen’s d Post hoc power
Body weight (kg) 61.3 ± 13.0 62.3 ± 12.1 0.05 0.99 0.50 0.50
Triglycerides (mg/dL) 117.5 ± 60.6 127.4 ± 58.0 0.51 0.49 0.16 0.10
HDL-C (mg/dL) 52.6 ± 15.7 53.3 ± 16.3 0.80 0.74 0.06 0.06
LDL-C (mg/dL) 120.7 ± 43.1 115.6 ± 49.1 0.49 0.80 0.17 0.10
ApoA-I (mg/dL) 145.9 ± 33.4 146.8 ± 34.2 0.87 0.78 0.04 0.05
Fasting glucose (mg/dL) 104.8 ± 20.0 104.4 ± 26.8 0.94 0.65 0.02 0.05
Hemoglobin A1c (%) 6.1 ± 0.6 6.0 ± 0.6 0.34 0.93 0.45 0.40
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DL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein choles
ardioprotective lipids [16,17]. The association between obe-
ity and low-grade inﬂammation has also been established [18],
nd CRP is a well-known marker of inﬂammation. However, in this
tudy, despite the fact that subjects gained a signiﬁcant amount of
ody weight during the smoking cessation process, they nonethe-
ess experienced a signiﬁcant increase in apoA-I and HDL-C levels
nd a signiﬁcant decrease in loge-CRP levels. This ﬁnding suggests
hat the positive antiatherogenic effects of smoking cessation far
utweigh the negative effects of any weight gain that may occur
uring the process.
Further, the present study demonstrated a signiﬁcant inverse
orrelation between apoA-I and CRP levels, and our ﬁndings are
ompatible with those of previous reports showing the anti-
nﬂammatory properties of apoA-I [1–4]. One possible explanation
or this phenomenon is that resolving the inﬂammation induced by
igarette smoking may have contributed to the increase in apoA-
levels and reduction in CRP levels, as observed in the success
roup. However, the precise mechanisms by which smoking ces-
ation leads to increased apoA-I levels are unclear; further, there
ay be other mechanisms at play besides those involved in resolv-
ng the inﬂammation induced by smoking. This seems particularly
Fig. 2. Correlation between serum apolipoprotein A-I (0.46 0.56 0.58
ApoA-I, apolipoprotein A-I; CRP, C-reactive protein.
likelygiven that incomparisonwith themediumeffect sizeof apoA-
I levels in the success group, the effect size of loge-CRP levels was
small. Previous studies have reported decreased adiponectin levels
in current smokers that can be reversed upon smoking cessation
[19], and Oku et al. found that adiponectin deﬁciency suppressed
apoA-I synthesis in the liver in animal experiments [20]. Theseﬁnd-
ings suggest that an increase in adiponectin levels also contributes
to an increase in apoA-I levels after smoking cessation.
Another notable ﬁnding of our study was that reducing the
number of cigarettes smoked per day did not lead to any signiﬁ-
cant short-term improvements in lipid proﬁles or loge-CRP levels.
Further, negligible effect sizes of apoA-I and HDL-C levels were
observed in the failure group, despite the meaningful effect sizes
of body weight and loge-CRP levels in this group and meaning-
ful effect size of apoA-I levels in the success group. The number
of subjects in the failure group was small; thus, it is possible that
apoA-I levels could have statistically increased given a larger sam-
ple size. However, even with a larger sample size, the increase
in apoA-I levels may not have been substantially meaningful,
considering the negligible effect size of apoA-I levels in the failure
group.
apoA-I) and loge-C-reactive protein (CRP) levels.
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It is known that apoA-I plays an essential role in the cardiopro-
ective action of HDL [21] and that apoA-I levels provide a good
stimate of HDL concentration [22]. Low apoA-I levels have been
hown to be more accurate than low HDL-C levels as a risk marker
or atherosclerosis and cardiovascular events [23,24]. HDL-C levels
re inﬂuenced not only by the number of HDL particles but also by
ther factors including cholesterol transfer protein activity [1,21].
his may account for the superior predictive value of apoA-I than
DL-C levels. Furthermore, HDL-C levels are still not considered as
primary target of therapy in the National Cholesterol Education
rogram guidelines and European Society of Cardiology/European
therosclerosis Society guidelines, because an increase in circu-
ating HDL-C levels does not necessarily decrease the risk of CHD
vents, CHD deaths, or mortality [25,26]. In contrast, major inter-
st is focused on apoA-1 mimetic peptides, which not only are
ctive in cellular cholesterol efﬂux but also exert antioxidative,
nti-inﬂammatory, and antithrombotic effects [27].
Several clinical trials of smoking cessation have revealed sub-
tantial reductions in the risk for cardiovascular events in those
ho quit smoking [28–30]. Observational data suggest that smok-
ng cessation reduces the risk for cardiovascular events and that
he decline in risk begins within months after quitting [25]. To
he best of our knowledge, the present study represents the ﬁrst
eport demonstrating that successful smoking cessation is signif-
cantly associated with an increase in serum apoA-I levels in the
hort term—just 12weeks after initiating treatment and as few as 4
eeks after achieving complete abstinence from smoking. We pre-
iously reported that low apoA-I levels predict adverse outcomes
n patients with nonischemic heart failure [31]. Therefore, such a
apid increase in apoA-I levels after smoking cessation is a promis-
ng ﬁnding that may contribute to positive outcomes in those with
ardiovascular disease.
There are several limitations to our study. First, this study was
imited by the small number of subjects, particularly in the failure
roup. We did not have sufﬁcient study subjects to stratify each
roup (i.e. by duration of smoking cessation in the success group
nd by the number of cigarettes smoked per day during smoking
essation therapy in the failure group). Thus, we could not perform
ultivariate analysis on the effect of smoking cessation therapy
n apoA-I levels. Second, the criteria for successful smoking ces-
ation were mainly dependent upon subjects’ self-reports of their
ehavior; therefore, there is a possibility that subjects who did not
xactly fulﬁll the success criteriawere treated as part of the success
roup. Third, in an outpatient clinic, we could not assess the role of
nvironmental confounders, such as nutrition intake and physical
ctivity, on lipid proﬁles. Further studies involving a larger sam-
le size and considering the effect of potential confounders should
elp in better elucidating the precise effects of smoking cessation
n apoA-I levels.
onclusion
Our ﬁndings suggest that successful smoking cessation therapy
ith varenicline improves serum apoA-I and HDL-C levels in the
hort term. Simply reducing the number of cigarettes smoked per
ay appears to be insufﬁcient to achieve an improvement in lipid
roﬁles and a reduction in the risk for cardiovascular events.
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